A Phase 2, Multicenter, Placebo-controlled, Double-blind, Randomized, Parallel-group Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Tolvaptan (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 27 Dec 2016 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.